Caring for Caregivers of Individuals With Alzheimer's Disease
Indiana University · NCT07486037
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–99 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 25
- US sites recruiting
- 1
- Study start
- March 1, 2026
- Record last updated
- May 11, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
What is this study about? This study is called the EMBRACE Study - A Virtual Community Empowerment Approach Integrating Tradition and Technology for Family Caregivers of Individuals with Alzheimer's Disease. It tests whether a home-based virtual exercise program can reduce depression and anxiety in family caregivers of people living with Alzheimer's disease and related dementias (ADRD).
Why is this study needed? Caring for a loved one with ADRD is demanding and is strongly linked to depression and anxiety. Regular exercise is one of the most effective ways to reduce these symptoms - but caregivers often cannot leave home to exercise due to the needs of their loved one, transportation concerns, and safety issues.
What does participation involve? Participants will be randomly assigned (like a coin flip) to one of two groups:
- EMBRACE group: 24 weekly virtual group exercise sessions over 3 months (about 1 hour each), using an at-home elliptical device provided by the study. Months 4-6 include weekly check-in calls to support independent exercise. Educational sessions on habit-building and goal-setting are included.
- Wait-list control group: Completes the same surveys and measurements; receives the program after data collection ends.
Who can join? Adults (18+) who are the primary unpaid caregiver for someone with ADRD, can read and speak English, and are healthy enough to exercise. Participants do not need to leave home - everything is virtual.
What is being measured? Exercise time (using a wearable device), symptoms of depression and anxiety, and whether the program is feasible and acceptable to participants.
Where is the study based? Indiana University Indianapolis. The study is conducted entirely virtually and remotely.
Being studied: Exercise
Conditions: Intervention Group; Treatment as Usual
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Self-identifies as African American
- Age 18 years or older
- Primary unpaid caregiver for an adult living with Alzheimer's disease or a related dementia (ADRD)
- Able to read and speak English
- Deemed sufficiently healthy to participate in exercise per the PAR-Q+ screening questionnaire
- Has access to an email address
Exclusion Criteria
- Diagnosed psychiatric illness
- Untreated severe major depression
- Currently receiving advanced cancer treatment or hospice care
- Currently receiving dialysis
- Severe hearing loss without hearing aids
- Severe vision impairment without corrective eyeglasses
- No access to a phone or email
- Unable to safely exercise based on PAR-Q+ screening
- Already meeting the recommended physical activity guidelines at the time of enrollment
Recruiting US locations
School of Health and Human Sciences
Indianapolis, IN 46240
Site contact: Navin Kaushal, PhD · 3174505240 · nkaushal@iu.edu
Study contacts (from the official record)
- Navin Kaushal, PhD, FACM,FAHA · 317 278-9598 · nkaushal@iu.edu
Similar studies in Indiana
All neurology studies in Indiana →- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Indianapolis, IN + 35 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Indianapolis, IN + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Regeneron Pharmaceuticals
- Location
- Indianapolis, IN + 41 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Indianapolis, IN + 24 other US sites
- Eligibility basics
- Ages 18–60